Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583227 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
A Phase 3 study of Eosinophilic Esophagitis, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 368
- Enrollment target
- 20
- Study locations
NCT05583227: Active Phase 3 study of Eosinophilic Esophagitis, sponsored by AstraZeneca.
NCT05583227 is a Phase 3 study of Eosinophilic Esophagitis that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 368 participants, below the 856-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05583227, a Phase 3 study of Eosinophilic Esophagitis, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 368 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Primary Outcome
Peak esophageal eosinophil count per HPF determined by histological analysis of 2-4 biopsies from each of the proximal, mid, and distal esophagus.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Tezepelumab
Study Locations (20)
Florida
- Research Site - Inverness
- Research Site - Jacksonville
- Research Site - Saint Augustine
Pennsylvania
- Research Site - Philadelphia
- Research Site - Smithfield
Arizona
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
California
- Research Site - Los Angeles
Colorado
- Research Site - Aurora
Illinois
- Research Site - Normal
Iowa
- Research Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2027-03-23 |
| Phase | Phase 3 |
What the registry record for NCT05583227 still lists
NCT05583227 is an interventional study that assigns participants to a tested intervention. The registered 368 participants enrollment target is mid-sized for trials with a published cap, below the 856-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05583227 names 20 study sites across 17 states, led by Florida, Pennsylvania, Arizona.
Frequently Asked Questions
What is clinical trial NCT05583227 about?
NCT05583227 is a clinical study titled "Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis". A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
What is the current status of trial NCT05583227?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 368 participants. The study started on 2022-11-10. Estimated completion is 2027-03-23.
What conditions does trial NCT05583227 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT05583227?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05583227?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05583227 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05583227's enrollment target sits among peer trials
368 9th of 44 higher than 35 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
RECRUITING · Phase 3
-
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
-
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
COMPLETED · Phase 3
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
RECRUITING
-
Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI